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1. INTRODUCTION 
Magnesium and calcium play an essential role in human and animal health and are 
provided in the case of deficiency syndromes and other diseases. Also aluminium (in the 
form of various salts, complexes or hydroxides) is commonly used as pharmaceutical 
substance. Their compounds are described in pharmacopoeias and are provided in 
pharmaceutical or/and food supplement formulations (mainly tablets, chewing tablets, 
suspension or solutions), alone or in combination, in relatively high amounts. In several cases 
a combination of these official compounds is formulated, for example magnesia, alumina and 
calcium carbonate tablets and suspensions. 
Evaporative Light Scattering Detection (ELSD) has been recently used in many 
chromatographic applications as a quasi-universal detector, especially in the case of the 
absence of chromophoric groups in the analytes molecules. Despite the wide use of ELSD in 
organic analysis (drugs, natural products, polymers), very few inorganic analytes have been 
determined using LC-ELSD methods [sulfate (as counter-ion of aminoglycoside antibiotics), 
sodium carbonate (in a drug substance)].  
In this paper an LC-ELSD method has been developed and validated for the 
simultaneous, simple, low operational costs and reliable determination of the main metals of 
pharmaceutical use (magnesium, calcium and aluminium) and its application in 
pharmaceutical and food supplement formulations. Using ion-exchange column and volatile 
acids as mobile phase the separation of the three metal ions is successful and the detection by 
ELSD is achieved at the µg ml-1 concentration level. 
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2. THEORETICAL PART 
2.1. MAGNESIUM, CALCIUM AND ALUMINIUM 
2 . 1 . 1 .  Magn e s i um  
Magnesium is an essential mineral for human nutrition mainly found in foods like 
cereals, nuts, cacao, meat, milk and vegetables. Magnesium has several important functions. It 
is involved in energy metabolism, acting as a metal activator or co-factor for enzymes 
requiring adenosine triphosphate (ATP), in replication of DNA and in the synthesis of RNA 
and proteins; it appears to be essential for all phosphate transferring systems. Together with 
calcium, magnesium is involved in muscle contraction and blood clotting [1][2]. Its deficiency 
occurs, in general as complications of other diseases like alcoholism, diabetes, and kidney 
failure and in some post-operative periods. Magnesium deficiency can be treated by oral or 
parental administration of some magnesium salts (magnesium supplement tablets). 
Oversupply in severe cases lead to coma and death [1]. 
 Pharmaceutically is magnesium used in the form of acetate, aspartate, carbonate, 
chloride, citrate, gluconate, glycerophosphate, hydroxide, oxide, phosphate, pidolate, 
salicylate, stearate, sulfate, trisilicate, etc. [3][4][5]. 
2 . 1 . 2 .  Ca l c i um  
Calcium is the most common mineral in the human body (approximately 99% of 
total body calcium is in the skeleton and teeth and 1% in blood and soft tissues) where it is 
present in almost the same relative abundance as in the earth’s crust. Dairy products are the 
most concentrated, well absorbed sources of calcium. Other foods which can contribute to 
dietary calcium include firm tofu (chemically set with calcium), dried beans, kale, broccoli, 
and bok choy. Calcium has four major biological functions: (1) structural as stores in the 
skeleton, (2) electrophysiological - carries charge during an action potential across 
membranes, (3) intracellular regulator, and (4) as a cofactor for extracellular enzymes and 
regulatory proteins. In this way it regulates heart rhythm; eases insomnia; helps regulate the 
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passage of nutrients in & out of the cell walls; assists in normal blood clotting; helps maintain 
proper nerve and muscle function; lowers blood pressure; important to normal kidney 
function [6] and in current medical research reduces the incidence of colon cancer [7], and 
reduces blood cholesterol levels [8]. Deficiency syndromes may result in arm and leg muscles 
spasms, softening of bones, back and leg cramps, brittle bones, rickets, poor growth, 
osteoporosis, tooth decay, depression. Dietary calcium deficiency also has been associated 
with increased risk of hypertension, preeclampsia, and colon cancer [6]. 
Pharmaceutically is calcium used in the form of carbonate, chloride, glubionate, 
gluceptate, gluconate, hydroxide, lactate, lactobionate, levulinate, pantothenate, phosphate, 
saccharate, etc. [3][4][5]. 
2 . 1 . 3 .  Alumin i um  
Aluminium is a trivalent cation found in its ionic form in most kinds of animal and 
plant tissues and in natural waters everywhere. It is the third most prevalent element and the 
most abundant metal in the earth’s crust. Dietary aluminium is ubiquitous, but in such small 
quantities that it is not a significant source of concern in persons with normal elimination 
capacity. If a significant load exceeds the body’s excretory capacity, the excess is deposited in 
various tissues, including bone, brain, liver, heart, spleen, and muscle. Lactate, citrate, and 
ascorbate all facilitate gastrointestinal absorption. No known physiologic need exists for 
aluminum; however, it is sometimes a competitive inhibitor of several essential elements of 
similar characteristics, such as magnesium, calcium, and iron. Mechanisms of toxicity include 
inhibition of enzyme activity and protein synthesis, alterations in nucleic acid function, and 
changes in cell membrane permeability. Aluminium toxicity is usually found in patients with 
impaired renal function. In aluminium-related disease, the predominant features are defective 
mineralization and osteomalacia with a closely associated dialysis encephalopathy, which is 
thought to be caused by aluminium deposition in the brain. Aluminium causes an oxidative 
stress within brain tissue, leading to the formation of Alzheimerlike neurofibrillary tangles 
[9][10]. Aluminium also has a direct effect on hematopoiesis [11]. 
Pharmaceutically is aluminium used in the form of hydroxide, acetate, 
chlorohydrate, phosphate, subacetate, etc. [3][4][5]. 
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2.2. DETERMINATION OF MAGNESIUM, CALCIUM AND 
ALUMINIUM 
The pharmacopoeial analytical methods [3][4][5] for the assay of the 
aforementioned metals in starting materials and formulations are complexometric titrations 
with disodium edetate (direct or back-titrations). In the case of combination of two metal 
compounds (e.g. magnesium and aluminium) different pH adjustments are used in separate 
titrations to obtain specificity. Atomic absorption spectrometry (AAS) is also widely used. 
For example in the alumina, magnesia and calcium carbonate combination, aluminium is 
determined  with edetate by back-titration at acidic buffer, calcium with edetate at very 
alkaline buffer and magnesium with  AAS at wavelength of 282.5 nm. 
From the above described official methods it is clear that in the case of metal 
combinations separate assay experiments are required, very often using different analytical 
techniques (titrimetry and AAS). Therefore an analytical method enabling the simultaneous 
determination of all metals in the formulation is very desirable. 
Several chromatographic techniques have been developed for the simultaneous 
determination of trace metal elements, metals of specific groups and metal speciation. These 
include gas chromatography (GC), HPLC interfaced to AAS, atomic emission (AES) and 
atomic fluorescence (AFS) spectrometry. Recent tandem analytical systems are based on 
HPLC – inductively coupled plasma mass spectrometry (ICP-MS) and HPLC – 
thermochemical hydride generation – AAS system [12]. 
Several reviews have been published on ion-pair chromatography of metal ions [13], 
directly coupled chromatography – atomic spectroscopy [14], ion-exchange HPLC of metal 
complexes [15], determination of metal ions by HPLC-photometry [16], ion-pair reversed-
phase chromatography of metal chelates [17], metal determination and metal speciation by 
LC [18], analysis of metal ions by HPLC [19],  HPLC-AAS hybrid technique for the 
speciation of trace metals in biological fluids [20], trace-elemental speciation by HPLC using 
microbore columns hyphenated to AAS [21],  chromatographic and hyphenated methods for 
elemental speciation analysis in environmental media [22], the coupling of size-exclusion 
HPLC with ICP MS in bio-inorganic analysis [23], chemical modification of analytes in 
speciation analysis by CE, LC and GC [24], HPLC-isotope dilution ICP-MS for speciation 
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studies [25],  bio-inorganic speciation analysis by hyphenated techniques [26], and separation 
and quantisation of low-molecular mass organic acid – metal complexes using HPLC and 
CZE for speciation purposes [27]. 
2 . 2 . 1 .  De t e rm ina t i o n  o f  Magn e s i um  
Out of Czech pharmacopoeia analytical method (complexometric titrations with 
disodium edetate at alkalic buffer [5]), several articles describing alternative determinations of 
magnesium in pharmaceutical preparations were published. These include AAS [1] sequential 
injection analysis (SIA) [1] and recently a multi-commutation-based flow system for multi-
element analysis also suitable for determination of calcium [28]. 
A variety of other instrumental methods is used for magnesium analysis in non-
pharmaceutical samples as beverages, food or body fluids. These include UV-VIS 
spectrophotometry [29], ion chromatography with a piezoelectric detector [30], ICP-AES 
[31], ICP-MS [32] and ion selective electrode [33]. Other methods used for magnesium 
analysis are based on flow based procedures, e.g. continuous on-line feedback based flow 
titration [34], FIA based on magnesium ion-selective electrode [35] and a multi-component 
flow injection based analysis with diode array detection [36]. Nevertheless, these methods 
have not been applied on determination of magnesium in pharmaceuticals. 
2 . 2 . 2 .  De t e rm ina t i o n  o f  Ca l c i um  
Czech officinal analytical method is complexometric titrations with disodium 
edetate in strongly alkalic contitions [5]. 
Other methods used for determination of calcium in pharmaceutical formulations 
and/or pharmaceutical raw materials ICP-MS and electrothermal atomic absorption 
spectrometry (ET AAS) [37], SIA [1], multi-commutation-based flow system for multi-
element analysis [28][38] and capillary isotachophoresis [39]. 
2 . 2 . 3 .  De t e rm ina t i o n  o f  A lum in i um  
Czech pharmacopoeia determination of Aluminium is based on back-titration of 
disodium edentate at acidic conditions [5]. 
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The commonly used analytical methods for the quantitative determination of 
aluminium are fluorimetry, AAS, AES, GC and induced plasma atomic emission 
spectrometry (ICP-AES). Although most of these are high precision methods, they 
necessitate pre-treatment steps, special and expensive instruments, large volumes of sample 
solution and a long period of analysis. Electrogravimetry and coulometric methods generally 
have moderate selectivity, sensitivity and speed. Strong buffering of some fixed pH is 
necessary to obtain reproducible data in polarography and voltammetric methods. Since the 
reduction of aluminium at the electrode in aqueous solutions is difficult, it cannot be easily 
determined by conventional voltammetry. Thermo gravimetric methods are largely limited to 
decomposition and oxidation reactions and such physical processes as vaporization, 
sublimation, and desorption. UV–VIS spectrophotometry is used due to its accuracy and 
good precision, associated with the low cost and widespread diffusion of equipment [40]. 
2.3. EVAPORATIVE LIGHT SCATTERING DETECTION 
2 . 3 . 1 .  I n t r o du c t i o n  
About twenty years have been past since the introduction of the first commercially 
available Evaporative Light Scattering Detector (ELSD) in early 1980s (Mass Detector, 
Applied Chromatography System Limited, Macclesfield, Cheshire, UK), and nowadays 
ELSDs have moved into the mainstream of HPLC detection techniques. The inherent 
advantage of ELSD to detect any analyte, regardless of the optical (i.e. UV absorptivity), 
electrochemical or other analyte properties, is the main reason for ELSD expanded 
applicability. ELSD is considered to be a quasi-universal rather than a fully universal detector, 
since analytes with higher volatility than the mobile phase can not be detected. It is mainly 
considered to be an LC detector. However it also appears compatibility with countercurrent 
(CCC) and supercritical fluid chromatography (SFC) [41]. 
Beyond the common usefulness, which any universal detector appear [e.g. refractive 
index detector (RID) and mass spectrometers (MS)], the increasing interest for ELSD is 
additionally attributed to some special characteristics: (a) compatibility with gradient elution 
and insensibility to temperature variation (unlike RID), (b) much better detectability than 
RID for most molecular classes, similar to conventional LC detectors (regular detection limit 
is in the nanogram range, depending on analyte volatility and relative molecular mass) and (c) 
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low cost and easy operation (unlike MS). However, it should be clarified that until now, 
ELSD is mainly considered to be a good alternative or supplemental detector rather than a 
substitute for the conventional HPLC detectors (UV-VIS, fluorimeters etc.), while it lacks the 
huge identification potential of the wide range of LC-MS techniques [41]. 
The operation principle of ELSD mainly consists of three successive processes 
depicted in Figure 2.1 (a) nebulization of the chromatographic effluent, (b) evaporation of 
the mobile phase, and (c) detection of the non-volatile residual particles, by means of the 
measurement of the scattered light [41]. 
 
Figure 2.1  Depiction of the main steps of the ELSD design type B operation. 
2 . 3 . 2 .  Nebu l i z a t i o n  
In the first step of ELSD detection mechanism, the effluent from a 
chromatographic column enters a Venturi-type nebulizer, where it is transformed into an 
aerosol. These nebulizers create a high flow of carrier gas (air or inert gas, such as nitrogen, 
carbon dioxide, argon or helium) over the liquid surface producing a high amount of droplets 
with remarkably uniform size [41].  
Distribution and mean values of droplets diameter are considered to be very critical 
parameters, which strongly influence the analytical characteristics (i.e. detectability, sensitivity 
and repeatability) of the ELSD methods. The formation of uniform, reproducible and stable 
aerosols depends on the relation of the nozzle diameter and the flow rates of mobile phase 
and nebulizing gas. For constant diameter of the nozzle, stable aerosols are formed only for a 
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limited range of flow rates, and further, the flow rate of the nebulizer gas must be adjusted in 
relation to the flow rate of the mobile phase. For a mobile phase flow rate of 1 ml min-1, the 
usual consumption of the nebulizing gas must be in the range of 2-5 l min-1 [41]. 
Furthermore, it has been indicated that mean diameter of aerosol droplets strongly 
influences ELSD response and in fact an increase of the mean diameter of aerosol droplets 
results in ELSD response enhancement [41].  
If the gas flow rate is too low, mobile phase would not be completely nebulized 
and/or it would not be completely vaporized, which would result in an excessive noise or 
baseline with spiked sharp peaks [41]. 
ELSDs are classified in two types according to their structure after the nebulization 
unit. In ELSD of type A (non aerosol splitting), the entire aerosol immediately enters the 
heated evaporation tube (drift tube), where the evaporation process begins. In ELSD of type 
B (aerosol splitting, Figure 2.1), the aerosol, before the evaporation step, enters a glass 
chamber or a focusing cone (nebulization chamber), in which the droplets of high size are 
condensed on the walls of the chamber and diverted to waste. The proportion of the wasted 
aerosol depends on mobile phase volatility and varies from > 90% (aqueous mobile phase) to 
< 10% (highly volatile organic solvents). Each type appears its own benefits, while the 
appropriate choice depends on the nature of the analyte and the composition of the mobile 
phase. ELSD of type B requires lower evaporation temperature than type A and thus it is 
more sensitive for volatile, semi-volatile or thermo-sensitive analytes. On the other hand, for 
non-volatile analytes, ELSD of type A appears to be more sensitive, since the entire quantity 
of analyte reaches the optical cell. Considering the composition and flow rate of the mobile 
phase, ELSD of type A is incompatible with gradient elution and requires low flow rates and 
highly volatile mobile phases (non-aqueous or low water portion), while ELSD of type B 
appears wider compatibility [41]. 
2 . 3 . 3 .  Evapo r a t i o n  o f  Mob i l e  Pha s e  
In this stage, the size of the aerosol droplets is reduced, due to the evaporation of 
the mobile phase, which is performed in a heated drift tube. Ideally, the purpose of this stage 
is to completely vaporise the mobile phase, without any analyte loss (due to evaporation or 
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thermal decomposition). The completeness of the mobile phase evaporation and the extent 
of loss of analyte is mainly determined by the evaporation temperature, which should be 
selected in accordance to the mobile phase and analyte volatility, to the mobile phase flow 
rate and to the ELSD type (A or B). Inappropriate selection of the evaporation temperature 
results, in case of low temperature, in an excessive noise or baseline with spiked sharp peaks, 
or in case of high temperature, in reduced sensitivity. Apart from the analyte loss, high 
evaporation temperature causes rigorous solvent evaporation, which destroys uniformity of 
particle size, and favours the formation of liquid rather than solid particles. Both effects 
result in decrease of ELSD sensitivity. The evaporation temperature is usually set between 30 
and 100°C. Decrease of the required evaporation temperature can be obtained with 
nebulizing gas of high thermal conductivity (helium was found to require at least 30°C lower 
evaporation temperature than carbon dioxide), which in cases of volatile and thermosensitive 
compounds results in enhancement of detector sensitivity. On the other hand, for stable and 
non volatile compounds, the ELSD response factor has been found to be independent of the 
nature of the nebulizing gas [41]. 
2 . 3 . 4 .  Li gh t  S c a t t e r i n g  
The aerosol, after the evaporation process, ideally composed by solid particles of 
analyte, enters the optical cell and passes through a light beam. The scattered light is 
measured by a photomultiplier or a photo diode, providing the output signal [41]. 
Light scattering processes are classified in two types: elastic scattering, in which the 
scattered radiation is of the same frequency as the incident radiation, and inelastic scattering, 
in which the scattered radiation is of a different frequency. In ELSDs, inelastic scattering is 
considered to be negligible and it is not further examined. Elastic scattering is classified in 
three types: Rayleigh, Debye and Mie. Refraction-reflection mechanism, which has its origin 
in the induced secondary emission of particles in the path of the incident beam, has also been 
reported as a potential mechanism of scattering in the ELSD optical cell [41].  
Since scattering and not absorbing phenomenon is intended to occur when the light 
interacts with the analyte particles, a tungsten filament or halogen lamp that produces a 
continuous spectrum of wavelengths, rather than a monochromatic laser-emitting diode, is 
favoured as a light source. In some instruments a secondary gas, independent of the 
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nebulizing gas, is used to concentrate the particles in the centre of the detection cell and to 
prevent the deposition on the cell inner surfaces [41]. 
The power of scattered light is controlled by the particle diameter, the light 
wavelength and the angle of scattered light. It has been observed that the ELSDs sensitivity 
is higher, but the dynamic range narrower, for low detection angle, with wide angular 
acceptance and the use of vertically polarized or unpolarized light [41]. 
2 . 3 . 5 .  Lim i t a t i o n s  
Apart from the fact that ELSDs appear nearly no selectivity, an inherent 
characteristic of most ‘universal’ detectors, some additional requirements may limit their 
applicability. The main difficulty for the development of LC-ELSD analytical methods is the 
restriction on the mobile phase volatility. Non-volatile modifiers, ion-pairing reagents, acids, 
bases and buffers cannot be used with ELSD. Therefore, a very useful part of the mobile 
phase chemistry is not compatible with ELSD, making quite difficult to convert an LC-UV 
method to an LC-ELSD method or to achieve efficient chromatographic separations for 
some type of analytes. Some acceptable volatile reagents are trifluoroacetic (TFA), 
heptafluorobutyric, nonafluoropentanoic (NFPA), acetic and formic acid and their 
ammonium salts in low concentrations (< 0.1 M) [41]. 
ELSD is a destructive detector, therefore it must be last in line if it is used in series 
with other detectors. In cases that it is used in line with another destructive detector (e.g. 
MS), a line splitter should be added and the flow rate of the nebulizating gas should be 
accordingly adjusted [41]. 
Generally, it appears relatively low detectability, inadequate for the direct analysis of 
compounds (e.g. impurities, residues) at ng ml-1 concentration level (quantitation limit is 
usually above 0.1 µg ml-1). In these cases, preconcentration steps should be developed, in 
order to enrich the under analysis samples. However, development of a preconcentration 
procedure is quite difficult, mainly for two reasons: firstly, non-volatile reagents can not be 
applied (e.g. precipitation reagents and buffers) and secondly, preconcentration procedure 
may simultaneously enrich some of the matrix components resulting in excessive 
interferences due to the low ELSD selectivity [41]. 
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2 . 3 . 6 .  App l i c a t i o n s  
ELSD has been effectively used for the determination of a wide variety of 
compounds in various synthetic or natural matrices. The main application areas of ELSD 
concern pharmaceuticals, foods and beverages, natural products and biological samples and 
polymers. A wide range of column types and mobile phase polarity have been utilized and 
various procedures for sample preparation have been developed depending on the analyte 
nature and the sample matrix. Beyond the differences of analyte and matrix nature, a 
common characteristic of all ELSD methods is the conformity with the following rule: “non 
volatile analytes are determined utilizing a volatile mobile phase” [41]. 
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3. EXPERIMENTAL PART 
3.1. CHEMICALS AND REAGENTS 
All chemicals were of analytical reagent grade. 
3 . 1 . 1 .  Wat e r  
HPLC grade water was prepared in three steps: (a) deionization, (b) distillation and 
(c) purification of HPLC grade. Tap water passed deionizating column Zalion 2.004 
purchased from IONEL A.E.B.E. company (N. Irakleio Attikis, Greece), then it  was 
distilled in “Mega-Pure automatic” distilling instrument manufactured by CORNING (New 
York, USA). Purification of HPLC grade was performed by Milli-Q R6 system made by 
MILLIPORE Corporation (Billerica, MA, USA). HPLC water was prepared within 15 days 
before use.   
3 . 1 . 2 .  Mob i l e  Pha s e  
Trifluoracetic acid (TFA) in purity > 98% (Sigma-Aldrich, St. Louis, USA) and 
nonafluoropentanoic acid (NFPA) in purity > 97% (Aldrich, Steinheim, Germany) were used 
for preparation of aqueous mobile phase. 
The examined mobile phases were prepared directly in HLPC system trough the 
medium of flown-channel selection valve diluting stock solutions by HPLC grade water in 
appropriate ratio. The following stock solutions were commonly used TFA 3.1 ml l-1 
(isocratic elution) 8.0 ml l-1 (gradient elution) and NFPA 6.2 ml l-1. 
For the reason that TFA and NFPA are highly volatile substances, their stock 
solutions were prepared by adding appropriate volume of acid to the volumetric flask 
(250 ml) almost full of already degassed HPLC grade water and filled with the same diluent 
to the punch mark. All stock solutions were kept in refrigerator in airtight container.  
3 . 1 . 3 .  S tanda r d s  
The standard solutions of metals were prepared from Magnesium acetate 
tetrahydrate in purity > 99% (Hopkin&Williams LTD, Chadwell Health, Essex, England), 
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Calcium hydroxide in purity > 96% and Aluminium Nitrate nonahydrat in purity > 98.5% 
(both from Merck, Darmstadt, Germany). Organic anion standards were prepared from 
L-Ascorbic acid in purity > 99%; DL-Aspartic acid in purity > 99% and Citric acid, 
monohydrate in purity > 98% (all three by Sigma-Aldrich, Steinheim, Germany). 
Magnesium (isocratic elution) 
Accurately weighted amount 0.0892 g of Magnesium acetate chemical was dissolved 
in mobile phase (TFA 11 mM l-1) and sonicated few minutes till complete dissolution, 
forming 100.1 µg ml-1 solution of Mg2+. From this stock solution, volumes of 0.8 ml, 1.0 ml, 
1.4 ml, 1.6 ml and 2.4 ml were taken by automatic pipette to 10 ml volumetric flasks, in order 
to gain working standard solutions of 8.0 µg ml-1; 10.0 µg ml-1; 14.0 µg ml-1; 16.0 µg ml-1 and 
24.0 µg ml-1 of magnesium. From these five dilutions the calibration curve for isocratic 
elution was constructed. 
Calcium 
The precise amount of Calcium hydroxide substance (0.1847 g) dissolved by mobile 
phase (TFA 11 mM l-1) in 100 ml volumetric flask and sonicated few minutes till complete 
dissolution for 959.2 µg ml-1 solution of Ca2+. From this stock solution, volumes of 0.375 ml, 
0.8 ml, 1.125 ml, 1.5 ml were taken by automatic pipette to 25 ml volumetric flasks and 
0.75 ml was taken by automatic pipette to 10 ml volumetric flasks, in order to gain working 
standard solutions of 14.4 µg ml-1; 28.8 µg ml-1; 43.2 µg ml-1; 57.6 µg ml-1 and 71.9 µg ml-1 of 
calcium cations. From these five dilutions the calibration curve was constructed. 
Magnesium and Aluminium (linear gradient elution) 
Standards substances of Magnesium acetate (0.0886 g) and Aluminium nitrate 
(0.2084 g) were weighted into two different 100 ml volumetric flasks and completely 
dissolved in mobile phase (TFA 12 mM l-1), using sonication,  forming 99.4 µg ml-1 of Mg2+ 
and 147.6 µg ml-1 of Al3+ stock solutions. From magnesium stock solution volumes of 0.6 ml, 
1.2 ml, 1.8 ml, 2.4 ml; 3.0 ml were taken by automatic pipette into 10 ml volumetric flasks 
and from aluminium stock solution volumes of 0.67 ml; 1.3 ml; 2 ml; 2.67 ml; 3.33 ml were 
taken by automatic pipette to the same 10 ml volumetric flasks, in order to gain mixed 
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working standard solutions of magnesium 6.0 µg ml-1; 11.9 µg ml-1; 17.9 µg ml-1; 23.9 µg ml-1; 
29.8 µg ml-1 and aluminium 9.9 µg ml-1; 19.6 µg ml-1; 29.5 µg ml-1; 39.4 µg ml-1; 49.2 µg ml-1. 
From these five dilutions the calibration curve for linear gradient elution was constructed. 
Organic acids 
Accurate amounts of organic acids (0.0149 g of DL-Aspartic acid; 0.0148 g of 
L-Ascorbic acid; 0.0168 g of Citric acid) were dissolved in HPLC grade water separately in 
three 100 ml volumetric flasks forming three stock solutions in concentrations 147.5 µg ml-1 
of Aspartic acid; 146.5 µg ml-1 of Ascorbic acid and 150.5 µg ml-1 of Citric acid. From stock 
solution of each acid was taken volume of 3.3 ml by automatic pipette into 10 ml volumetric 
flask, in order to gain mixed working standard solutions of Aspartic acid 49.2 µg ml-1; 
Ascorbic acid 48.8 µg ml-1 and Citric acid 50.2 µg ml-1. These solutions were used to observe 
retention times and separation of organic acids. 
3 . 1 . 4 .  Oth e r  Ch em i c a l s   
Calcium lactate (Mallinckrodt Chemical Works) during development of method. 
Hydrochloric acid fuming 37%; Formic acid 98 - 100% and Acetic acid in purity > 99.5% (all 
three from Merck, Darmstadt, Germany) were used to improve separation of metals from 
drug matrix. 
3.2. INSTRUMENTATION 
3 . 2 . 1 .  HPLC Sy s t em  
Modular Shimadzu HPLC system (Tokyo, Japan) consisting of a LC-10AD VP 
pump; a FCV-10AD VP flow-channel selection valve and a RHEODYNE 7725i by Perkin 
Elmer (Wellesley, MA, USA) manual injector with a built-in position sensing switch, which 
provided the chromatograph start signal. The complete filling method with 20 µl loop was 
used. Syringe containing excess of sample was required to completely flush mobile phase 
from the loop and the volume of the loop was injected. 
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3 . 2 . 2 .  Chr oma t o g r aph i c  Co l umn  
IONPAC® CS – 14 analytical column by DIONEX® is a moderately hydrophilic, 
carboxylate-functionalized cation exchanger. Its packing is an 8.0 µm diameter macroporous 
particle consisting of ethylvinylbenzene crosslinked with 55% divinylbenzene. The substrate 
is functionalized with hydrophilic carboxylic acid, which permits the elution of monovalent 
and divalent cations. Dimensions are 4 × 250 mm with 1300 µeq capacity. 
3 . 2 . 3 .  ELSD De t e c t o r  
Evaporative Light Scattering Detector (ELSD) was SEDEX 75 (S.E.D.E.R.E., 
Alfortville Cedex, France). The nebulizing gas was nitrogen. Appropriate pressure drop was 
applied at the end of the flow line in order to ensure the complete removal of the gas wastes. 
3 . 2 . 4 .  So f twa r e  
The data from HPLC system were compiled by Class VP Chromatography Data 
System, version 4.3; (Shimadzu, Germany). 
Statistics were performed by StatMost Analysis and Graphics, version 2.50 
(DataMost Corporation, Dataxiom Software Inc., LA, USA). 
3.3. PROCEDURES 
3 . 3 . 1 .  Gen e r a l  P r o c e du r e s  
Analytical column, which was utilized, is polymeric one, resistant to strongly acidic 
environment. After the measuring day column was carefully washed with mobile phase for 20 
minutes, flow rate 1.5 ml min-1 and it was stored in the same medium, since the applied 
mobile phase contained a strong acid (TFA). Before measurements, flow path was rinsed 
with mobile phase for about 15 min, until baseline noise became negligible (less than 5 mV at 
detector gain 11). 
In case of linear gradient elution, equilibration of the analytical column was required 
between runs. Equilibration was performed at a flow rate of 2.0 ml min-1 in two successive 
steps: (a) HPLC grade water for 15 minutes and (b) mobile phase for 15 minutes with 
composition identical to the composition of gradient program start.  
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Degassing was carried using Helium air-leak tube of another HPLC system for five 
minutes. 
The detector was necessary to switch on at least two hours before measurements, 
due to lamp aging, in order to stabilise the light intensity. When measuring sooner, there was 
a higher response of the detector which caused bigger areas of peaks and significant 
inaccuracy of results.  
3 . 3 . 2 .  Opt ima l  Mob i l e  Pha s e  and  Ch r oma t o g r aph i c  Pa r ame t e r s  
The optimum composition of mobile phase was aqueous solution of 0.85 ml l-1 
TFA for the analysis of Milk of Magnesia® and Tums® by the means of isocratic elution. For 
the analysis of Aludrox® linear gradient elution was used; from 0 min to 6th using TFA 
0.96 ml l-1 as mobile phase, from 6th min to 7th min linear gradient to aqueous TFA 6.4 ml l-1. 
Flow rate of mobile phase during the analyses was 1.0 ml min-1, corresponding to a 
back pressure of 1330 psi. Column was operating at laboratory temperature. 
Gain of the detector was set on 11. It was the best compromise between sensitivity 
and baseline noise occurrence. Its working temperature was 70 centigrade for the reason that 
mobile phase used contains a high portion of water which is not as volatile as organic 
solvents and analytes were not declinable to decomposing. Pressure of the nebulizing gas was 
3.5 Bars. 
3 . 3 . 3 .  Val i da t i o n  P r o c e du r e s  
The LC-ELSD analytical method was validated in terms of resolution and 
symmetry of chromatographic peaks, precision (repeatability and reproducibility), 
concentration range, correlation coefficient of calibration curve, detectability and accuracy.  
Since ELSD is not a linear detector, double logarithmic relations were established 
and correlation coefficients were determined for magnesium, calcium and aluminium by 
triplicate measurements of the corresponding chromatographic peaks of five standard 
solutions. 
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Repeatability of the method was evaluated by replicate measurements of standard 
solutions (n=3) and repeated analyses of pharmaceutical formulations (3 independent sub-
samples × 3 measurements). 
Reproducibility of the method was evaluated by the estimation of %RSD of the 
peak area of standard solutions and the slope of calibration curves obtained at three different 
days within a week, with 3 replicates per day. 
Detection limit was determined as the analyte concentration for which the area of 
the chromatographic peak was equal to 3.3 times the standard deviation of the most dilute 
standard and was practically equal to the concentration having S/N ratio equal to 3.3. 
Quantification limit was determined as the analyte concentration for which the 
area of the chromatographic peak was equal to 10 times the standard deviation of the most 
dilute standard and was practically equal to the concentration having S/N ratio equal to 10. 
Accuracy was evaluated by recovery experiments. Formulation samples were 
fortified by standard solutions at three concentration levels, with three samples being 
prepared at each level and measured in triplicate. Mean recovery and range of recovery values 
were calculated. Accuracy was also evaluated by comparison of the results for magnesium, 
calcium and aluminium analyzed by the Pharmacopoeia [3][5] and the proposed method. 
3 . 3 . 4 .  Pha rma c e u t i c a l  Fo rmu l a t i o n s  
Following pharmaceutical formulations were submitted to trials; Milk of Magnesia® 
and Tums® (both by GlaxoSmithKline) and Aludrox® (Wyeth Hellas AEBE). All three 
pharmaceutical formulations have registration in Greece. 
Milk of Magnesia® 
active substance: Magnesium Hydroxide 425 mg  in 5 ml 
excipients: Water 
 Calcium Hypochloride 
manufacturer: GlaxoSmithKline 
dosage form: Suspension 
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Since this is higher density suspension, the representative volume (15.0 ml) was 
required for sampling. This volume, containing 531.3 mg of Mg2+ (according to label 
content), was added by pipette into 250 ml volumetric flask with mobile phase in addition 
acidified by 3.5 ml of TFA in order to neutralize concentrated solution of Magnesium 
Hydroxide. Volumetric flask was put into ultrasonic bath for five minutes and after filled to 
punch mark in with mobile phase setting in 2125.1 µg ml-1 solution of Mg2+. Still very 
concentrated solution had to been diluted by mobile phase again. Volume of 10.0 ml was 
pipetted into 100 ml volumetric flask and was prepared 212.5 µg ml-1 solution of Mg2+ used 
for further particular runs dilutions. The volumes of 0.375 ml; 0.47 ml and 0.75 ml were 
taken by automatic pipette into 10 ml volumetric flasks, in order to gain run solutions of 
Mg2+ in concentrations 8.0 µg ml-1; 10.0 µg ml-1 and 15.9 µg ml-1. 
For every day, a new two-point calibration curve was constructed 
Tums® 
active substance: Calcium Carbonate 600 mg in 1 tablet 
 Magnesium Carbonate 125 mg in 1 tablet 
excipients: Sodium Bicarbonate 
 Malic Acid 
 Microtal DCE Sugar 
 Saccharin Sodium 
 Magnesium Stearate 
 Orange Flavour 
 Talc 
manufacturer: GlaxoSmithKline 
dosage form: chewing tablets 
 
Pre-treatment of sample started with weighting of 10 tablets. From this quantity, 
mean tablet was found (1.4974 g), after that were tablets finely pulverized in ceramic bowl. 
Calcium and magnesium were quantified separately in different days, because of greatly 
different content in formulation. 0.9996 g (for calcium trial) and 1.0004 g (for magnesium 
trial) of powder was dissolved in 100 ml volumetric flask by mobile phase (TFA 10 mM l-1) 
and additionally acidified by 0.80 ml of TFA according to calculations. This extra amount of 
acid was used in order to neutralize basic solution of carbonates. Generated stock solutions 
in concentration of 1603.9 µg ml-1 Ca2+ and 240.8 µg ml-1 Mg2+ (according to label content) 
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were sonicated for 15 min to release ions from insoluble excipients into solution. Turbidity of 
insoluble excipients was removed by centrifuging for 15 min with consequent membrane 
filtration (Millipore, 0.45 µm). Further dilutions of filtrated solutions were made taking 
0.1 ml; 0.25 ml; 0.4 ml for calcium and 0.4 ml; 0.65 ml; 0.9 ml for magnesium into 10 ml 
volumetric flasks for individual runs. Concentrations of 16.0 µg ml-1; 40.1 µg ml-1; 
64.2 µg ml­1 for calcium and 9.6 µg ml-1; 15.7 µg ml-1; 21.7 µg ml-1 for magnesium. 
For every day, a new two-point calibration curve was constructed. 
Aludrox® 
active substance: Aluminium Hydroxide 233.00mg in 1 tablet 
 Magnesium Hydroxide 83.46mg in 1 tablet 
excipients: Confectioner’s Sugar 
 Starch Maze 
 Talc 
 Calcium Stearate 
 Saccharin Sodium 
 Hydrogenated Vegetable Oil 
 Peppermint Oil 
 Flavour compound 
manufacturer: Wyeth Hellas AEBE 
dosage form: chewing tablets 
 
Ten tablets were weighed on analytical scales, mean tablet weight was found 
(0.9170 g) and after that were tablets finely pulverized in a ceramic bowl. Accurately 0.7036 g 
and 0.7005 g of the powder was added into 100 ml volumetric flasks for pre-treatment of 
two samples in different days. The tablet powder was dissolved in HPLC grade water with 
addition of 3.0 ml of hydrochloric acid 37%, in order to obtain entire quantity of ions from 
matrix. Gained solutions in concentration of 618.4 µg ml-1 respectively 615.7 µg ml-1 of Al3+ 
and 376.1 µg ml-1 respectively 374.5 µg ml-1 of Mg2+ were sonicated in ultrasonic bath for 
15 min in order to discorporate the aggregates. The volumetric flasks were filled with HPLC 
grade water up to the punch mark. The suspension was filtered through a membrane filter 
(Millipore, 0.45 µm) in order to get rid of insoluble particles of excipients and to gain the 
clear stock solutions of ions. The filtrate volume of 0.5 ml for each sample was taken by 
automatic pipette into 10 ml volumetric flask and diluted by mobile phase, in order to gain 
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solutions of 30.9 µg ml-1 and 30.8 µg ml-1 for aluminium; 18.8 µg ml-1 and 18.7 µg ml-1 for 
magnesium. 
For every day, a new two-point calibration curve was constructed. 
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4. RESULTS AND DISCUSSION 
4.1. METHOD OPTIMALIZATION 
4 . 1 . 1 .  Sepa r a t i o n  o f  Mg 2 +  and  Ca 2 +   
Standard solutions of magnesium acetate and calcium lactate were analysed in order 
to determinate the retention time of magnesium and calcium and their corresponding 
resolution in various TFA mobile phases (Table 4.1). The best result was achieved with TFA 
0.085 % (v/v) aqueous mobile phase, resulting sufficient difference in retention times 
(magnesium 7.0 min, calcium 7.9 min), good resolution (1.7) and symmetry (magnesium 0.9, 
calcium 0.9) was obtained. Lower concentration of TFA in mobile phase means extension of 
retention time, cut-down of peak area and downgrade of peak symmetry. Reversely higher 
concentration gives shorter time and much superior response with better symmetry, but 
unfortunately defies coincidental magnesium and calcium quantification. 
Improvement of separation was examined using an eluting ion of higher molecular 
weight (NFPA). In this case, a double separation mechanism was able to be performed: (a) 
cation exchange between metal cations and protons and (b) reversed phase chromatography 
due to the adsorption of the lipophilic complexes of [metal(NFPA)n]2-n to the polymeric 
stationary phase. Addition of NFPA increased retention time, but had undesirable influence 
on the peak symmetry (Table 4.1). Best results were obtained with TFA-NFPA mixed mobile 
phase, TFA 0.100 % (v/v) and NFPA 0.015 % (v/v), in which the NFPA was responsible 
for the adsorption procedure, while TFA provided the adequate mobile phase acidity for the 
cation exchange mechanism. 
Table 4.1 Influence of mobile phase composition on retention time, resolution and 
asymmetry factor for magnesium and calcium 
Retention time (min) Asymmetry Factor Mobile Phase 
Composition 
(% v/v) Magnesium Calcium 
Resolution 
Magnesium Calcium 
7.2 8.3 1.9 0.9 1.0 
7.0 7.9 1.7 0.9 0.9 
TFA 0.077 
0.085 




0.015 6.8 7.7 1.8 1.0 1.0 
 31
Retention time (min) Asymmetry Factor Mobile Phase 
Composition 






0.031 9.2 10.7 1.7 0.8 1.0 
 
 
Figure 4.1 Typical chromatogram of magnesium (Rt=7.0 min); calcium (Rt=7.9 min) and 
noise peak in void volume using DIONEX® IONPAC® CS – 14 analytical column and aqueous 
mobile phase containing 0.085% (v/v) TFA. 
4 . 1 . 2 .  Sepa r a t i o n  o f  Or g an i c  An i on s  ( c i t r i c ,  a s c o r b i c ,  a s p a r t i c )  
Since occurrence of organic anions in pharmaceutical formulations is common, 
their separation was examined, by analysing standard stock solutions of ascorbic, aspartic and 
citric acid. Different concentrations of TFA, acetic acid and formic acid were examined, but 
separation of organic anions peaks was never adequate for ascorbate and aspartate. On the 
other hand, citrate was completely separated from ascorbate and aspartate. Organic anions 
are keeping similar retention time, practically independently on concentration of TFA, due to 
cation-exchange character of the column. Best separation was observed for mobile phase 
containing acetic acid 0.077 % (v/v). 
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Table 4.2  Influence of mobile phase composition on retention time for ascorbic, aspartic 
and citric acid 
Retention time (min) Mobile Phase 
Composition 
(% v/v) Ascorbate Aspartate Citrate 
2.5 2.9 3.2 
2.5 2.8 3.2 




0.092 2.5 2.7 3.2 
Formic Acid 0.077 2.6 2.9 3.5 
2.1 2.4 3.3 Acetic Acid 0.077 
0.092 2.2 2.4 3.4 
Table 4.3 Influence of mobile phase composition on resolution and asymmetry factor for 
ascorbic, aspartic and citric acid 
Resolution Asymmetry Factor Mobile Phase 
Composition 
(% v/v) Asc/Asp Asp/Cit Ascorbate Aspartate Citrate 
1.3 1.1 0.9 0.9 1.3 
1.2 1.3 1.0 0.9 1.1 




0.092 0.7 1.9 1.3 - 1.1 
Formic Acid 0.077 1.1 1.7 0.9 1.2 1.1 
1.2 3.6 1.0 1.4 1.0 Acetic Acid 0.077 
0.092 1.1 3.8 1.0 1.3 1.1 
 
Figure 4.2 Typical chromatogram of ascorbic acid (Rt=2.5 min), aspartic acid (Rt=2.7 min) 
and citric acid (Rt=3.2 min) using DIONEX® IONPAC® CS – 14 analytical column and aqueous 
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mobile phase containing 0.092% v/v TFA. There is not analyzed noise peak after the peaks of 
organic acid. 
4 . 1 . 3 .  Sepa r a t i o n  o f  Mg 2 + ;  Ca 2 +  and  A l 3 +  b y  L in e a r  Grad i e n t  
E lu t i o n  
The standard solutions of Magnesium acetate, Calcium hydroxide and Aluminium 
nitrate, dissolved in TFA 0.085 % (v/v) mobile phase, were used for experiments. Mixed run 
dilution of standards was injected in conditions, which were searched out as ideal for 
magnesium and calcium separation, aqueous TFA around 0.085 % (v/v), to observe 
separation of aluminium, but it was not eluted from the column. It was needed a gradient 
elution using high concentration of TFA, in order to suppress retention of aluminium in the 
column. Examination of several linear gradients (Table 4.4 and Table 4.5) led to optimal one: 
from 0 min to 6th min aqueous TFA 0.096 % (v/v) mobile phase, between 6th min and 
7th min was performed the linear gradient change to aqueous TFA 0.640 % (v/v). Resulting 
retention times were 6.2 min for magnesium, 7.1 min for calcium and 11.4 min for 
aluminium. Resolution was magnesium/calcium (1.8), calcium/aluminium (8.8) and 
asymmetry factors were magnesium (1.0), calcium (1.2) and aluminium (1.6). This linear 
gradient setting had sufficiently separated three metals in one run. Disadvantage was high 
retention time instability of magnesium and calcium, in the course of even slightly 
modification of TFA concentration. On the other hand retention time of aluminium was 
robust and method provided good detector response for all metals. 
Table 4.4 Influence of mobile phase composition and different linear gradient settings on 
retention times for magnesium, calcium and aluminium 
Retention time (min) Time 
(min) 
Mobile Phase Composition 




















Table 4.5 Influence of mobile phase composition and different linear gradient settings on 
resolution and asymmetry factor for magnesium, calcium and aluminium 
Resolution Asymmetry Factor Time 
(min) 
Mobile Phase Composition 
















TFA 0.640 1.8 8.8 1.0 1.2 1.6 
 
 
Figure 4.3 Typical chromatogram of magnesium(Rt=6.2 min), calcium (Rt=7.1 min) and 
aluminium (Rt=11.4 min) using DIONEX® IONPAC® CS – 14 analytical column and gradient 
elution program: from 0 min to 6 min 0.096% (v/v) TFA aqueous mobile phase and from 6 min to 
7 min linear gradient to aqueous 0.640% (v/v) TFA aqueous mobile phase. Small peak of TFA is 
visible (Rt=10.8 min) due to the gradient procedure. 
4 . 1 . 4 .  I nn e r  S t anda r d  Me th od  
Addition of calcium inner standard was used for Aludrox® formulation, since 
difficulties with quantification of magnesium appeared. It was used to prove that magnesium 
complexes with TFA are not adsorbing on lipophilic excipients of formulation, because 
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calcium forms similar complexes and should be adsorbed by the same mechanism. Recovery 
of calcium standard addition was 100%. 
4.2. VALIDATION 
4 . 2 . 1 .  Re s o l u t i o n  and  As ymme t r y  
Resolution ( R ) of two neighbouring peaks was studied on standard solutions, 









=   
 
where 1Rt  and 2Rt  are the retention time of the peaks and 1w  and 2w  the 
corresponding peak width at 10% of the peak height. 
Asymmetry factor ( sA ) determined according to the Equation 4.2 in 0.1 high ( h ) 
of the peak, 
Equation 4.2 
b
aAs =  
where a is the front part and b is the tail path of the peak width in 0.1 high, splitted 
by the middle line of the peak.  
Results are presented on Table 4.6 and Table 4.7 There is a lower resolution, than 
optimal 2.0, between magnesium and calcium. However the time difference is still sufficient 
for simultaneous quantification of both metals. The standards for isocratic elution were 
measured in different days, that causing nuances in chromatographic conditions (especially 
composition of mobile phase). Asymmetry factors values are in the optimal range (0.9 – 1.2) 
except of aluminium (1.6). This is probably caused by the aging of chromatographic column. 
Table 4.6 Resolution and asymmetry for magnesium and calcium; isocratic elution 
 Magnesium Calcium 
Concentration (µg ml-1) 7.8 14.4 
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 Magnesium Calcium 
Mobile phase (% v/v) TFA 0.085 TFA 0.085 
Retention time (min) 7.0 7.9 
Width 10% 0.52 0.53 
Resolution 1.7 
Asymmetry 0.9 0.9 
Table 4.7 Resolution and asymmetry factors for magnesium, calcium and aluminium; linear 
gradient elution 
 Magnesium  Calcium  Aluminium 
Concentration (µg ml-1) 9.9  14.4  14.9 
Mobile phase (% v/v) *  *  * 
Retention time (min) 6.2  7.1  11.4 
Width 10% 0.46  0.53  0.44 
Resolution  1.8  8.8  
Asymmetry 1.0  1.2  1.6 
* gradient elution program: from 0 min to 6 min 0.096% (v/v) TFA aqueous mobile 
phase and from 6 min to 7 min linear gradient to aqueous 0.640% (v/v) TFA aqueous 
mobile phase 
4 . 2 . 2 .  Lin ea r i t y  and  Ran g e  
Very good correlation was achieved with the well-established exponential 
relationship between peak area ( A ) and analyte mass (m ) (Equation 4.3). The linearity of the 
method was calculated by using the linear least squares regression technique of the logarithm 
of peak area ( A ) versus the logarithm of analyte concentration ( c ) (Equation 4.4), 
Equation 4.3 bmaA ×=     
Equation 4.4 acbA logloglog +=  
where a and b are coefficients depending on the ELSD instrumentation and on 
nebulizative and evaporative processes (flow rates of the nebulization gas, flow rate of mobile 
phase, composition of the mobile phase, evaporation temperature, etc.). 
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Standard solutions were measured in triplicate. The regression data are presented in 
Table 4.8. The calibration curve of magnesium using linear gradient elution is depicted in 
Figure 4.4. 
















6.0 - 29.8 4.855 (±0.032) 
1.554 
(±0.026) 0.9995 
Calcium 14.4 - 71.9 4.291 (±0.053) 
1.584 
(±0.033) 0.9993 























Figure 4.4 Calibration curve of  magnesium; linear gradient elution 
4 . 2 . 3 .  Pr e c i s i o n  
Repeatability of the method was evaluated by replicate measurements of standard 
solutions, n=3-5 (Table 4.9). Reproducibility of the method was evaluated by the estimation 
of % RSD of the slope of calibration curves obtained at three different days within a week, 
with 3 replicates per day (Table 4.10). 
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Table 4.9 Precision of HPLC-ELSD determination of magnesium, calcium and aluminium 
 Concentration Level 
(µg ml-1) 
% RSD n 
Magnesium   8.0 2.01 4 
Calcium 14.4 2.42 5 
Aluminium   9.9 5.73 3 
Table 4.10 Slope % RSD of HPLC-ELSD calibration curves of magnesium, calcium and 
aluminium 
 Day 1 Day 2 Day 3 % RSD 
Magnesium 
(isocratic elution) 
1.466 1.596 1.605 4.99 
Magnesium 
(gradient elution) 
1.554 1.646 1.544 3.55 
Calcium 1.585 1.601 1.499 3.50 
Aluminium 1.148 1.259 1.197 4.65 
4 . 2 . 4 .  De t e c t a b i l i t y  
Detection and quantification limits, with statement about number of replication, are 
presented in Table 4.11. 
Table 4.11 Detectability of HPLC-ELSD determination of magnesium, calcium and 
aluminium 
 LOD (µg ml-1) LOQ (µg ml-1) n 
Magnesium 
(isocratic elution) 
1.25 2.65 4 
Magnesium 
(gradient elution) 
0.58 1.18 3 
Calcium 2.86 5.76 5 
Aluminium 2.03 5.45 3 
 
Owing to good properties of the detector, all of the assessed ions can be 
determined very sensitively with ELS detection.  
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4.3. RESULTS OF ANALYSES 
4 . 3 . 1 .  Mi lk  o f  Magn e s i a ®  
The formulation was analysed according to the new HPLC-ELSD method. The 
results obtained from the assay of magnesium revealed conformance to the European 
Pharmacopoeia [3]. The general chapter of pharmacopoeia is requiring the active substance 
content in formulation within the range of 95.0 – 105.0 % of the labelled content. Individual 
values are presented Table 4.12. Typical chromatogram of the analysis is depicted on Figure 
4.7. 
Table 4.12 Comparison of the HPLC-ELSD assay results to the label content; Milk of 
Magnesia® 



























The accuracy of the new HPLC-ELSD method was evaluated by recovery 
experiments. Samples were fortified by adding known amounts of magnesium standard. Five 
spiked samples were prepared. The good accuracy of the proposed method was confirmed 
since the individual recovery values are within the range of 95 – 105 % (except of one 
measurement, which is minutely outstanding) (Table 4.13). 
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Further study of the matrix effect on the determination was carried out by dilution 
experiments (determination of magnesium content using a varying dilution factor D 
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(Vinitial/Vfinal) at three different levels). The correlation curve of the concentration found (in 
the diluted solution) versus D was linear (r > 0.95) with a slope equal to the content of the 
formulation and a statistically (proven by t-test) zero intercept. Similarly, the correlation curve 
of formulation content found versus D was very linear with statistically (proven by t-test) 
zero slopes. These results confirmed the absence of any constant or proportional determinate 
error due to matrix (excipients) effect (Table 4.14; Table 4.15 and Table 4.16). 
Table 4.14 Dependence of run concentration and formulation concentration on dilution 
factor; Milk of Magnesia® 

























Magnesium 0.76 0.41 1.862 2264.33 73.75 0.9994 
* For a 3-point curve, the limit of t-test value is 4.303 with the confidence 95%. 
 
Figure 4.5 Dependence of run concentration on dilution factor; Milk of Magnesia® 
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Table 4.16 Dependence of formulation concentration on dilution factor; Milk of Magnesia® 
 Parameter a Std. Dev. a Parameter b Std.Dev. b tb* 
Magnesium 32648.53 1911.22 466846.96 344372.79 1.356 
* For a 3-point curve, the limit of t-test value is 4.303 with the confidence 95%. 
 
Figure 4.6 Dependence of formulation concentration on dilution factor; Milk of Magnesia® 
 
Figure 4.7 Typical chromatogram of Milk of Magnesia® trial using DIONEX® IONPAC® 
CS – 14 analytical column and isocratic elution 0.085% (v/v) TFA aqueous mobile phase. 
Magnesium (Rt=6.6 min) and not analyzed noise peak ahead of magnesium peak. 
 42
4 . 3 . 2 .  Tums  ®  
The formulation was analysed according to the new HPLC-ELSD method. The 
results obtained from the assay of calcium and magnesium revealed conformance to the 
European Pharmacopoeia [3]. The general chapter of pharmacopoeia is requiring the active 
substance content in one tablet within the range of 95.0 – 105.0 % of the labelled content, 
for tables its weight is greater than 250 mg. Individual values are presented in Table 4.17. A 
typical chromatogram of the analysis is depicted on Figure 4.10. 
Table 4.17 Comparison of the HPLC-ELSD assay results to the label content; Tums® 
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The accuracy of the new HPLC-ELSD method was evaluated by recovery 
experiments. Samples were fortified by adding known standard amounts of calcium and 
magnesium. For each component, five spiked samples were prepared. An excellent accuracy 
of the proposed method was confirmed since the individual recovery values are within the 
range of 97 – 103 % (Table 4.18). 




































Magnesium  4.0 
10.0 
18.0 
  4.0 








  97.63 










Further study of the matrix effect on the determination was carried out by dilution 
experiments (determination of calcium and magnesium content using a varying dilution 
factor D (Vinitial/Vfinal) at three different levels). The correlation curve of the concentration 
found (in the diluted solution) versus D was linear (r > 0.95) with a slope equal to the 
content of the formulation and a statistically (proven by t-test) zero intercept. Similarly, the 
correlation curve of formulation content found versus D was very linear with statistically 
(proven by t-test) zero slopes. These results confirmed the absence of any constant or 
proportional determinate error due to matrix (excipients) effect (Table 4.19; Table 4.20 and 
Table 4.21). 
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Calcium 0.40 1.77 0.2227 1621.67 63.70 0.9992 
Magnesium 0.23 0.69 0.3332   240.40 10.16 0.9991 
* For a 3-point curve, the limit of t-test value is 4.303 with the confidence 95%. 
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Figure 4.8 Dependence of run concentration on dilution factor; Tums® 
Table 4.21 Dependence of formulation concentration on dilution factor; Tums® 
 Parameter a Std. Dev. a Parameter b Std. Dev. B tb* 
Calcium 162649.67 7429.90 37466.67 266889.78 0.1404 
Magnesium   24534.83 1047.09   2100.00   15369.06 0.1366 
* For a 3-point curve, the limit of t-test value is 4.303 with the confidence 95%. 
      
Figure 4.9 Dependence of formulation concentration on dilution factor; Tums® 
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Figure 4.10 Typical chromatogram of Tums® trial using DIONEX® IONPAC® CS – 14 
analytical column and isocratic elution 0.085% (v/v) TFA aqueous mobile phase. Magnesium 
(Rt=6.8 min); calcium (Rt=7.7 min); peaks of excipients (Rt=2.0 min and Rt=3.0 min) and not 
analyzed noise peak between peaks of second excipient and magnesium.  
4 . 3 . 3 .  Alud r ox ®  
The formulation was analysed according to the new HPLC-ELSD method. The 
results obtained from the assay of aluminium revealed conformance to the European 
Pharmacopoeia [3]. The general chapter of pharmacopoeia is requiring the active substance 
content in one tablet within the range of 95.0 – 105.0 % of the labelled content, for tables its 
weight is greater than 250 mg. 
Detected quantity of magnesium was lower than was declared. Despite of maximal 
effort to find the reason for low gain of magnesium from the formulation, it was not 
successful. The supposition that magnesium complexes with TFA may be retented in 
lipophilic excipients and removed by centrifuging was not confirmed. Calcium inner standard 
technique was used, but calcium standard recovery from sample was 100%. The most 
probable explication is the lower magnesium content or magnesium occurrence in different 
form, than is declared on the formulation label. It’s not possible to discover the truth reason 
without the detailed date about formulation composition from the producer or confrontation 
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with another analytical method. Individual values are presented in Table 4.22. A typical 
chromatogram of the analysis is depicted on Figure 4.11. 
Table 4.22 Comparison of the HPLC-ELSD assay results to the label content; Aludrox® 

































The accuracy of the new HPLC-ELSD method was evaluated by recovery 
experiments. Samples were fortified by adding known standard amounts of aluminium and 
magnesium. For each component, four spiked samples were prepared. A good accuracy of 
the proposed method was confirmed since the individual recovery values for aluminium are 
within the range of 95 – 105 % (except of one measurement) Recovery values of magnesium 
were out of the range (Table 4.18). 
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Figure 4.11 Typical chromatogram of Aludrox® trial using DIONEX® IONPAC® CS – 14 
analytical column and gradient elution program: from 0 min to 6 min 0.096% (v/v) TFA aqueous 
mobile phase and from 6 min to 7 min linear gradient to aqueous 0.640% (v/v) TFA aqueous 
mobile phase. Magnesium (Rt=6.2 min); aluminium (Rt=11.3 min); peaks of excipients 
(Rt=2.0 min; Rt=7.2 min and Rt=4.7 min); peak of TFA (Rt=10.8 min) and not analyzed noise 
around 9. min. 
 
Figure 4.12 Typical chromatogram of Aludrox® with addition of calcium inner standard using 
DIONEX® IONPAC® CS – 14 analytical column and gradient elution program: from 0 min to 6 
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min 0.096% (v/v) TFA aqueous mobile phase and from 6 min to 7 min linear gradient to aqueous 
0.640% (v/v) TFA aqueous mobile phase. Magnesium (Rt=6.2 min); calcium (Rt=7.1 min); 




According to pharmacopoeia two or more individual methods are required for 
simultaneous determination of metal cations. Cation exchange HPLC-ELSD isocratic and 
linear gradient methods developed and validated in this paper shows, that simultaneous 
determination of magnesium and calcium (isocratic method) or magnesium, calcium and 
aluminium (linear gradient) can be reliably achieved. Also standards of organic acids were 
examined in order to observe separation abilities of cation exchange analytical column in this 
application, because metal cations in form of organic salts or inorganic salt with certain 
organic component are commonly contained in pharmaceutical formulations. Nevertheless 
no method simultaneously determining both inorganic cation and organic anion had been 
published. This paper reveals strong advantage of this method-potential efficiency to 
determine metal cations and organic anions in one injection. However this utilization of 
HPLC-ELSD methods must be further investigated and validated before its application on 
pharmaceutical formulations. HPLC-ELSD methods are able to determine several analytes in 
one step, simply, rapidly and for low cost. They have very easy sample pretreatment, 
requiring no derivatization of analyte as it is common for spectrometric methods. Direct 
determination saves the time and lowers the expenses for analyses. HPLC-ELSD method 




Magnesium a kalcium hrají esenciální roli v existenci živých organismů. Magnesium, 
se účastní kolem 300 základních enzymatických reakcí, je důležité pro energetický 
metabolismus, zastává klíčovou roli v neurotransmisi, při imunitních funkcích a regulaci 
neuromuskulární aktivity srdce. Kalcium kromě strukturální, elektrofyziologické a 
intracelulárně regulační funkce je také kofaktorem extracelulárních enzymů a regulačních 
proteinů. Rovnováha těchto minerálů v těle naplňuje důležitou podmínku potřebnou 
k udržení zdraví. Jejich nedostatek nebo naopak nadbytek v organismu je spojen s řadou 
vážných syndromů a onemocnění. Aluminium neplní žádnou fyziologickou funkci, důležité je 
z hlediska jeho toxikologie. Magnesium, kalcium a aluminium jsou využívány samostatně 
nebo v kombinaci ve formě různých solí, oxidů, hydroxidů nebo komplexů při výrobě 
mnoha farmaceutických přípravků nebo potravinových doplňků. 
Český lékopis 2005 používá ke stanovení magnesia, kalcia a aluminia 
chelatometrickou titraci edetanem disodným (přímou nebo zpětnou). Další metody užívané 
k detekci magnesia, kalcia nebo aluminia jsou například ASS, ET-AAS, SIA s UV-VIS 
detekcí, multikomponentní FIA s detekcí diodovým polem, FIA za iontově selektivní 
elektrodové detekce, iontově selektivní elektrody, iontová chromatografie s piezoelektrickou 
detekcí, ICP-AES nebo MS, kapilární isotachoforéza a jiné elektrogravimetrické, 
coulometrické, polarografické, voltmetrické nebo thermogravimetrické metody. Používané 
metody bývají často spojeny s řadou nevýhod. Vzorky kovových kationů je například nutné 
před stanovením náročně a zdlouhavě upravovat nebo metoda vyžaduje drahé vybavení, 
proto bylo jedním z cílů této práce vyvinout a validovat jednoduchou a rychlou přímou 
metodu bez vysokých nároků na vybavení. 
Metoda je založena na spojení iontově výměnné HPLC s ELSD (Evaporative Light 
Scattering Detector). ELS detektor je quasi-univerzální detektor, který v současné době 
nachází stále širší uplatnění, a to především u analytů, které nemají ve své molekule 
chromoforové skupiny a nemohou být tudíž bez derivatizace detekovány 
spektrofotometricky. Oproti ostatním univerzálním detektorům, jako např. refraktometrický 
(RID) nebo MS, vykazuje určité přednosti: a) kompatibilita s gradientovou elucí (na rozdíl od 
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RID); b) podstatně lepší detektabilitu ve srovnání s RID (běžný limit detekce se pohybuje 
v nanogramových množstvích, v závislosti na těkavosti a molekulové hmotnosti); c) nízké 
náklady a snadná obsluha (na rozdíl od hmotnostního spektrometru). Nicméně ELSD 
vykazuje také určité nevýhody. Tou hlavní je požadavek na těkavost mobilní fáze. Nesmí být 
použity netěkavé reagenty, pufry ani jiné složky mobilní fáze. Výběr vhodných kyselin a bazí 
se tím značně omezuje; mezi často používané patří kyselina octová, mravenčí, triflouroctová, 
pentaflouropropionová a heptaflouromáselná a jejich amonné soli v nízkých koncentracích 
(<0,1 M). ELSD je destruktivní detektor, proto musí být poslední v řadě, pokud je použit 
v sérii s jinými detektory. Vykazuje také nedostatečnou detektabilitu pro analýzu např. 
nečistot a reziduí, které se vyskytují v množstvích ng ml-1 (LOQ je obvykle vyšší než 
0,1 µg ml-1). Tyto vzorky je obvykle třeba upravit prekoncentrací, což bývá obtížné, neboť 
není možné použít netěkavé reagencie. Základní princip detektoru sestává ze tří následných 
kroků: a) nebulizace chomatografického eluentu; b) vypaření mobilní fáze a c) detekce 
netěkavých částic na základě rozptylu světla. 
Pro separaci byla použita kationtově výměnná analytická kolona IONPAC® CS – 14 
od firmy DIONEX® s karboxylovými funkčními skupinami. 
Dobré rozlišení píků hořčíku a vápníku bylo kritickou podmínkou při hledání 
optimálního složení mobilní fáze. Nejlépe se osvědčila vodná mobilní fáze s TFA 
v koncentraci 0,085 % (v/v). Vyzkoušena byla také kombinace TFA/NFPA, ale rozdíly 
v retenčních časech a rozlišení byly minimální (Table 4.1). Předmětem výzkumu byly i 
organické aniony, proto proběhlo testování separační schopnosti metody v případě 
organických kyselin (Table 4.2, Table 4.3). Používaná analytická kolona je primárně určena 
k analýze jednomocných a dvojmocných kationů, přesto se podařilo užitím lineárního 
gradientu stanovit hliník. Program lineárního gradientu začínal s koncentrací 0,096% (v/v) 
TFA ve vodné mobilní fázi a mezi 6. – 7. minutou od nástřiku se koncentrace plynule 
změnila na 0,640% (v/v) TFA. V jednom měření je takto možné stanovit hořčík, vápník i 
hliník (Table 4.4, Table 4.5). 
Vyvinuté metody se podařilo úspěšně validovat pro užití v analýze léčivých 
přípravků. Přípravky obsahující hořčík a/nebo vápník (Milk of Magnesia®, Tums®) byly 
analyzovány metodou isokratickou, k analýze léčivých přípravku obsahujícího hliník 
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(Aludrox®) byla použita lineárně gradientová metoda. Pro obě metody byly určeny validační 
parametry rozlišení a asymetrie (Table 4.6, Table 4.7), linearita a rozsah (Table 4.8), přesnost 
z hlediska opakovatelnosti (Table 4.9) a reprodukovatelnosti (Table 4.10), limity detekce a 
kvantifikace (Table 4.11). 
Validované metody byly použity k analýze tří léčivých přípravků registrovaných 
v Řecku. Jednalo se o suspenzi Milk of Magnesia®, účinná látka: hydroxid hořečnatý 425 mg 
v 5 ml suspenze; žvýkací tablety Tums®, účinné látky: uhličitan vápenatý 600 mg a uhličitan 
hořečnatý 125 mg v 1 tabletě; žvýkací tablety Aludrox®, účinné látky: hydroxid hlinitý 233 mg 
a hydroxid horečnatý 83 mg v 1 tabletě (viz 3.3.4 Pharmaceutical Formulations). Při analýze 
se porovnávaly naměřené koncentrace iontů v přípravku s údajem od výrobce. Podle 
požadavků řeckých norem pro registrované léčivé přípravky musí být údaje ve shodě 
v rozmezí 95 - 105% obsahu. Tři vzorky z každého léčivých přípravků ve třech různých 
koncentracích byly změřeny většinou ve třech replikacích. Obsahovému kritériu odpovídaly 
všechny kovové kationy (Table 4.12 a Table 4.17) s výjimkou hořčíku u přípravku Aludrox® 
(Table 4.22). Důvod nižšího naměřeného obsahu v léčivém přípravku se nepodařilo zjistit. 
Poté co byla vyloučena adsorpce komplexů hořečnatých kationů s TFA na lipofilní excipienty 
léčivého přípravku změnou úpravy vzorku a použitím vnitřního standardu vápníku, je možné 
uvažovat o nepřesnosti v udání složení ze strany výrobce. Případně by bylo nutné pokusit se 
stanovit hořečnaté kationy jinou metodou a porovnat zjištěné výsledky. Dalším předmětem 
analýzy bylo měření pěti vzorků s přídavkem standardu příslušného kationu. Stanovení 
proběhlo většinou ve třech replikacích a opět vyhovovaly všechny vzorky kromě hořčíku u 
přípravku Aludrox® (Table 4.13, Table 4.18 a Table 4.23). Z naměřených údajů (Table 4.14, 
Table 4.19) byla pomocí t-testu hodnocena významnost odchylky u parametru a od nulové 
hodnoty pro závislost koncentrace vzorku na obrácené hodnotě jeho zředění (Table 4.15, 
Table 4.20) a významnost odchylky u parametru b od nulové hodnoty pro závislost 
koncentrace formulace na obrácené hodnotě jeho zředění (Table 4.16, Table 4.21). Všechny 
hodnoty byly menší než 4,303; což je maximální hodnota předepsaná pro tři měření 
zajišťující konfidenční interval 95%. 
Přestože hořčík a vápník se v léčivých přípravcích často vyskytují ve 
formě organických solí nebo přípravek s anorganicky vázaným kovem obsahuje navíc 
organický anion, nebyla dosud publikovaná žádná metoda stanovující anorganický kation i 
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organický anion současně. Každý z iontů bylo potřeba kvantifikovat odděleně. Tato práce 
poskytuje údaje pro další výzkum v oblasti, tak aby bylo možno s nenáročným vybavením 
stanovit v jednom nástřiku kationický i anionický komponent, metodu validovat a v další fázi 
ji aplikovat na farmaceutické přípravky. Prezentovaná metoda dokazuje, že hořčík, vápník a 
hliník lze, volbou správných podmínek, spolehlivě separovat a kvantifikovat využitím iontově 
výměnné chromatografie, za současného výskytu anorganického anionu. Měření standardů 
organických kyselin (aspartát, askorbát, citrát) teoreticky dokazuje, že by ani výskyt 
organického anionu v přípravku neměl bránit současnému stanovení kationické i anionické 
složky účinné látky léčivého přípravku. Hlavní výhodou metody je rychlost, snadná úprava 
vzorků, značná přesnost, dostatečná citlivost a nízké náklady na přístrojové vybavení. 
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